Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity

Blood

Volumn 116, Issue 4, 2010, Pages 603-613

  Wichmann, Christian ^a   Becker, Yvonne ^a   Chen Wichmann, Linping ^a   Vogel, Vitali ^b   Vojtkova, Anna ^a   Herglotz, Julia ^a   Moore, Sandra ^a   Koch, Joachim ^a   Lausen, Jörn ^a   Mäntele, Werner ^b   Gohlke, Holger ^b,c,d   Grez, Manuel ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CELL PROTEIN; DIMER; DNA; HYBRID PROTEIN; PROTEIN ETO; TETRAMER; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; MUTANT PROTEIN; ONCOPROTEIN; RUNX1T1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; GENE EXPRESSION; LEUKEMIA; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STABILITY; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CELL CULTURE; CELL DIFFERENTIATION; CELL STRAIN K 562; CELL STRAIN U937; CELL TRANSFORMATION; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN MULTIMERIZATION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; HUMANS; K562 CELLS; LEUKEMIA; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MUTANT PROTEINS; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPPING; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION FACTORS; U937 CELLS;

EID: 77956017878     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-10-248047     Document Type: Article

References (53)

1. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278(5340):1059-1064. (Pubitemid 27517875)
2. Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer. 2003;3(2):89-101.
3. Yan M, Burel SA, Peterson LF, et al. Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proc Natl Acad Sci U S A. 2004;101(49):17186-17191.
4. Yan M, Kanbe E, Peterson LF, et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med. 2006;12(8):945-949.
5. Zhang J, Kalkum M, Yamamura S, Chait BT, Roeder RG. E protein silencing by the leukemogenic AML1-ETO fusion protein. Science. 2004;305(5688):1286-1289. (Pubitemid 39129232)
6. Gardini A, Cesaroni M, Luzi L, et al. AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets. PLoS Genet. 2008;4(11):e1000275.
7. Ahn EY, Yan M, Malakhova OA, et al. Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis. Proc Natl Acad Sci U S A. 2008;105(44):17103-17108.
8. Hug BA, Lazar MA. ETO interacting proteins. Oncogene. 2004;23(24):4270-4274.
9. Lutterbach B, Westendorf JJ, Linggi B, et al. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol. 1998;18(12):7176-7184.
10. Hildebrand D, Tiefenbach J, Heinzel T, Grez M, Maurer AB. Multiple regions of ETO cooperate in transcriptional repression. J Biol Chem. 2001;276(13):9889-9895. (Pubitemid 33649205)
11. Lausen J, Cho S, Liu S, Werner MH. The nuclear receptor co-repressor (N-CoR) utilizes repression domains I and III for interaction and co-repression with ETO. J Biol Chem. 2004;279(47):49281-49288.
12. Liu Y, Cheney MD, Gaudet JJ, et al. The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity. Cancer Cell. 2006;9(4):249-260.
13. Yan M, Ahn EY, Hiebert SW, Zhang DE. RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis. Blood. 2009;113(4):883-886.
14. Wichmann C, Chen L, Heinrich M, et al. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells. Cancer Res. 2007;67(5):2280-2289.
15. Rhoades KL, Hetherington CJ, Harakawa N, et al. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood. 2000;96(6):2108-2115.
16. Heidenreich O, Krauter J, Riehle H, et al. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood. 2003;101(8):3157-3163.
17. Clackson T, Wells JA. A hot spot of binding energy in a hormone-receptor interface. Science. 1995;267(5196):383-386.
18. Bogan AA, Thorn KS. Anatomy of hot spots in protein interfaces. J Mol Biol. 1998;280(1):1-9.
19. Gonzalez-Ruiz D, Gohlke H. Targeting protein-protein interactions with small molecules: challenges and perspectives for computational binding epitope detection and ligand finding. Curr Med Chem. 2006;13(22):2607-2625. (Pubitemid 44364140)
20. Case DA, Cheatham TE 3rd, Darden T, et al. The Amber biomolecular simulation programs. J Comput Chem. 2005;26(16):1668-1688.
21. Cornell WD, Cieplak CI, Bayly IR, et al. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc. 1995;117(19):5179-5197.
22. Simmerling C, Strockbine B, Roitberg AE. Allatom structure prediction and folding simulations of a stable protein. J Am Chem Soc. 2002;124(38):11258- 11259.
23. Schuck P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys J. 2000;78(3):1606-1619.
24. Schuck P, Perugini MA, Gonzales NR, Howlett GJ, Schubert D. Size-distribution analysis of proteins by analytical ultracentrifugation: strategies and application to model systems. Biophys J. 2002;82(2):1096-1111. (Pubitemid 34111246)
25. Tonks A, Tonks AJ, Pearn L, Mohamad Z, Burnett AK, Darley RL. Optimized retroviral transduction protocol which preserves the primitive subpopulation of human hematopoietic cells. Biotechnol Prog. 2005;21(3):953-958.
26. Kwok C, Zeisig BB, Qiu J, Dong S, So CW. Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes. Proc Natl Acad Sci U S A. 2009;106(8):2853-2858.
27. Gohlke H, Kiel C, Case DA. Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. J Mol Biol. 2003;330(4):891-913.
28. Archontis G, Simonson T, Karplus M. Binding free energies and free energy components from molecular dynamics and Poisson-Boltzmann calculations: application to amino acid recognition by aspartyl-tRNA synthetase. J Mol Biol. 2001;306(2):307-327. (Pubitemid 33032882)
29. Hendsch ZS, Tidor B. Electrostatic interactions in the GCN4 leucine zipper: substantial contributions arise from intramolecular interactions enhanced on binding. Protein Sci. 1999;8(7):1381-1392.
30. Cheng CK, Li L, Cheng SH, et al. Transcriptional repression of the RUNX3/AML2 gene by the t(8;21) and inv(16) fusion proteins in acute myeloid leukemia. Blood. 2008;112(8):3391-3402.
31. Huang G, Zhang P, Hirai H, et al. PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat Genet. 2008;40(1):51-60.
32. Okumura AJ, Peterson LF, Okumura F, Boyapati A, Zhang DE. t(8;21)(q22;q22) fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression. Blood. 2008;112(4):1392-1401.
33. Tahirov TH, Inoue-Bungo T, Morii H, et al. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta. Cell. 2001;104(5):755-767.
34. Burel SA, Harakawa N, Zhou L, Pabst T, Tenen DG, Zhang DE. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol. 2001;21(16):5577-5590. (Pubitemid 32702461)
35. Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MA, Nimer SD. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood. 2002;99(1):15-23.
36. Hug BA, Lee SY, Kinsler EL, Zhang J, Lazar MA. Cooperative function of Aml1-ETO corepressor recruitment domains in the expansion of primary bone marrow cells. Cancer Res. 2002;62(10):2906-2912.
37. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell. 2002;1(1):63-74.
38. Missimer JH, Steinmetz MO, Baron R, et al. Configurational entropy elucidates the role of salt-bridge networks in protein thermostability. Protein Sci. 2007;16(7):1349-1359. (Pubitemid 46984869)
39. Moriggl R, Sexl V, Kenner L, et al. Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell. 2005;7(1):87-99.
40. Bravo J, Li Z, Speck NA, Warren AJ. The leukemia-associated AML1 (Runx1)-CBF beta complex functions as a DNA-induced molecular clamp. Nat Struct Biol. 2001;8(4):371-378.
41. Tang YY, Shi J, Zhang L, et al. Energetic and functional contribution of residues in the core binding factor beta (CBFbeta) subunit to heterodimerization with CBFalpha. J Biol Chem. 2000;275(50):39579-39588. (Pubitemid 32058984)
42. Tang YY, Crute BE, Kelley JJ, et al. Biophysical characterization of interactions between the core binding factor alpha and beta subunits and DNA. FEBS Lett. 2000;470(2):167-172.
43. Zelent A, Greaves M, Enver T. Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene. 2004;23(24):4275-4283.
44. Zhao X, Ghaffari S, Lodish H, Malashkevich VN, Kim PS. Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat Struct Biol. 2002;9(2):117-120.
45. Peczuh MW, Hamilton AD. Peptide and protein recognition by designed molecules. Chem Rev. 2000;100(7):2479-2494.
46. Toogood PL. Inhibition of protein-protein association by small molecules: approaches and progress. J Med Chem. 2002;45(8):1543-1558.
47. Erlanson DA, McDowell RS, O'Brien T. Fragment-based drug discovery. J Med Chem. 2004;47(14):3463-3482.
48. Li Y, Huang Y, Swaminathan CP, Smith-Gill SJ, Mariuzza RA. Magnitude of the hydrophobic effect at central versus peripheral sites in protein-protein interfaces. Structure. 2005;13(2):297-307. (Pubitemid 40247705)
49. Arkin MR, Randal M, DeLano WL, et al. Binding of small molecules to an adaptive protein-protein interface. Proc Natl Acad Sci U S A. 2003;100(4):1603-1608.
50. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov. 2004;3(4):301-317.
51. Minucci S, Maccarana M, Cioce M, et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell. 2000;5(5):811-820.
52. Lin RJ, Evans RM. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell. 2000;5(5):821-830.
53. So CW, Cleary ML. Dimerization: a versatile switch for oncogenesis. Blood. 2004;104(4):919-922.